| pubmed-article:19279329 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19279329 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19279329 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:19279329 | lifeskim:mentions | umls-concept:C0026986 | lld:lifeskim |
| pubmed-article:19279329 | lifeskim:mentions | umls-concept:C0368761 | lld:lifeskim |
| pubmed-article:19279329 | lifeskim:mentions | umls-concept:C0333684 | lld:lifeskim |
| pubmed-article:19279329 | lifeskim:mentions | umls-concept:C1334894 | lld:lifeskim |
| pubmed-article:19279329 | lifeskim:mentions | umls-concept:C2348499 | lld:lifeskim |
| pubmed-article:19279329 | lifeskim:mentions | umls-concept:C0681842 | lld:lifeskim |
| pubmed-article:19279329 | lifeskim:mentions | umls-concept:C0449297 | lld:lifeskim |
| pubmed-article:19279329 | lifeskim:mentions | umls-concept:C1521828 | lld:lifeskim |
| pubmed-article:19279329 | pubmed:issue | 21 | lld:pubmed |
| pubmed-article:19279329 | pubmed:dateCreated | 2009-5-27 | lld:pubmed |
| pubmed-article:19279329 | pubmed:abstractText | Mutations in the NPM1 gene represent the most frequent genetic alterations in patients with acute myeloid leukemia (AML) and are associated with a favorable outcome. In 690 normal karyotype (NK) AML patients the complete remission rates (CRs) and the percentage of patients with adequate in vivo blast cell reduction 1 week after the end of the first induction cycle were significantly higher in NPM1(+) (75% and 80%, respectively) than in NPM1(-) (57% and 57%, respectively) patients, but were unaffected by the FLT3-ITD status. Multivariate analyses revealed the presence of a NPM1 mutation as an independent positive prognostic factor for the achievement of an adequate day-16 blast clearance and a CR. In conclusion, NPM1(+) blast cells show a high in vivo sensitivity toward induction chemotherapy irrespective of the FLT3-ITD mutation status. These findings provide insight into the pathophysiology and help to understand the favorable clinical outcome of patients with NPM1(+) AML. | lld:pubmed |
| pubmed-article:19279329 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19279329 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19279329 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:19279329 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19279329 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19279329 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19279329 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19279329 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19279329 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19279329 | pubmed:month | May | lld:pubmed |
| pubmed-article:19279329 | pubmed:issn | 1528-0020 | lld:pubmed |
| pubmed-article:19279329 | pubmed:author | pubmed-author:BerdelWolfgan... | lld:pubmed |
| pubmed-article:19279329 | pubmed:author | pubmed-author:BuechnerThoma... | lld:pubmed |
| pubmed-article:19279329 | pubmed:author | pubmed-author:HeineckeAchim... | lld:pubmed |
| pubmed-article:19279329 | pubmed:author | pubmed-author:HiddemannWolf... | lld:pubmed |
| pubmed-article:19279329 | pubmed:author | pubmed-author:SpiekermannKa... | lld:pubmed |
| pubmed-article:19279329 | pubmed:author | pubmed-author:Feuring-Buske... | lld:pubmed |
| pubmed-article:19279329 | pubmed:author | pubmed-author:BuskeChristia... | lld:pubmed |
| pubmed-article:19279329 | pubmed:author | pubmed-author:BohlanderStef... | lld:pubmed |
| pubmed-article:19279329 | pubmed:author | pubmed-author:BraessJanJ | lld:pubmed |
| pubmed-article:19279329 | pubmed:author | pubmed-author:UnterhaltMich... | lld:pubmed |
| pubmed-article:19279329 | pubmed:author | pubmed-author:SchneiderStep... | lld:pubmed |
| pubmed-article:19279329 | pubmed:author | pubmed-author:HosterEvaE | lld:pubmed |
| pubmed-article:19279329 | pubmed:author | pubmed-author:DufourAnnikaA | lld:pubmed |
| pubmed-article:19279329 | pubmed:author | pubmed-author:SauerlandMari... | lld:pubmed |
| pubmed-article:19279329 | pubmed:author | pubmed-author:FritschSusann... | lld:pubmed |
| pubmed-article:19279329 | pubmed:author | pubmed-author:MellertGudrun... | lld:pubmed |
| pubmed-article:19279329 | pubmed:author | pubmed-author:BenthausTobia... | lld:pubmed |
| pubmed-article:19279329 | pubmed:author | pubmed-author:SchneiderFrie... | lld:pubmed |
| pubmed-article:19279329 | pubmed:author | pubmed-author:ZellmeierEvel... | lld:pubmed |
| pubmed-article:19279329 | pubmed:author | pubmed-author:WoermannBernh... | lld:pubmed |
| pubmed-article:19279329 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19279329 | pubmed:day | 21 | lld:pubmed |
| pubmed-article:19279329 | pubmed:volume | 113 | lld:pubmed |
| pubmed-article:19279329 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19279329 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19279329 | pubmed:pagination | 5250-3 | lld:pubmed |
| pubmed-article:19279329 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:19279329 | pubmed:meshHeading | pubmed-meshheading:19279329... | lld:pubmed |
| pubmed-article:19279329 | pubmed:meshHeading | pubmed-meshheading:19279329... | lld:pubmed |
| pubmed-article:19279329 | pubmed:meshHeading | pubmed-meshheading:19279329... | lld:pubmed |
| pubmed-article:19279329 | pubmed:meshHeading | pubmed-meshheading:19279329... | lld:pubmed |
| pubmed-article:19279329 | pubmed:meshHeading | pubmed-meshheading:19279329... | lld:pubmed |
| pubmed-article:19279329 | pubmed:meshHeading | pubmed-meshheading:19279329... | lld:pubmed |
| pubmed-article:19279329 | pubmed:meshHeading | pubmed-meshheading:19279329... | lld:pubmed |
| pubmed-article:19279329 | pubmed:meshHeading | pubmed-meshheading:19279329... | lld:pubmed |
| pubmed-article:19279329 | pubmed:meshHeading | pubmed-meshheading:19279329... | lld:pubmed |
| pubmed-article:19279329 | pubmed:meshHeading | pubmed-meshheading:19279329... | lld:pubmed |
| pubmed-article:19279329 | pubmed:meshHeading | pubmed-meshheading:19279329... | lld:pubmed |
| pubmed-article:19279329 | pubmed:meshHeading | pubmed-meshheading:19279329... | lld:pubmed |
| pubmed-article:19279329 | pubmed:meshHeading | pubmed-meshheading:19279329... | lld:pubmed |
| pubmed-article:19279329 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19279329 | pubmed:articleTitle | NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). | lld:pubmed |
| pubmed-article:19279329 | pubmed:affiliation | Department of Medicine III, University Hospital Munich, Germany. | lld:pubmed |
| pubmed-article:19279329 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19279329 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:4869 | entrezgene:pubmed | pubmed-article:19279329 | lld:entrezgene |
| entrez-gene:2322 | entrezgene:pubmed | pubmed-article:19279329 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:19279329 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:19279329 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:19279329 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19279329 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19279329 | lld:pubmed |
